Anzeige
Mehr »
Sonntag, 05.07.2026 - Börsentäglich über 12.000 News
Milliardenkonkurrenten im Visier: Dieser KI-Wert gewinnt namhafte Großkunden!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41XT7 | ISIN: KYG4790P1037 | Ticker-Symbol: O15
Tradegate
03.07.26 | 10:14
4,180 Euro
+0,48 % +0,020
Branche
Gesundheitswesen
Aktienmarkt
ASIEN
1-Jahres-Chart
INSILICO MEDICINE CAYMAN TOPCO Chart 1 Jahr
5-Tage-Chart
INSILICO MEDICINE CAYMAN TOPCO 5-Tage-Chart
RealtimeGeldBriefZeit
4,1404,20004.07.
4,1004,20003.07.

Aktuelle News zur INSILICO MEDICINE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoTakeda Makes Fresh AI Drug Discovery Bet With Insilico Medicine10
DoTakeda, Insilico sign AI drug discovery pact worth up to $600M7
DoInsilico Medicine, Takeda partner on AI-driven drug discovery7
DoInsilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery217Partnership to leverage Pharma.AI platform for novel drug candidates across Takeda's therapeutic areas CAMBRIDGE, Mass., July 1, 2026 /PRNewswire/ -- Insilico Medicine...
► Artikel lesen
DoINSILICO Opens 10.75% Higher After Inking USD600M AI-powered Drug Discovery Strategic Partnership with Takeda11
DoINSILICO (03696): VOLUNTARY ANNOUNCEMENT INSILICO MEDICINE AND TAKEDA ACHIEVED STRATEGIC AI-POWERED DRUG DISCOVERY COLLABORATION WORTH UP TO USD600 MILLION1
INSILICO MEDICINE Aktie jetzt für 0€ handeln
DiINSILICO (03696): VOLUNTARY ANNOUNCEMENT VOLUNTARY EXTENSION OF LOCK-UP UNDERTAKINGS GIVEN BY CEOS2
26.06."Götter-Medikament": Dieser KI-Konzern jagt das größte Versprechen der Medizin694© Foto: Vladimir Borovic - Adobe StockDer KI-Pharmaspezialist InSilico setzt auf Langlebigkeitsmedizin, Milliarden-Partnerschaften und China. Das Ziel: profitabel werden und die Branche verändern.Der...
► Artikel lesen
23.06.SK Biopharmaceuticals Partners with Insilico for AI CNS Drugs4
23.06.Insilico Medicine, SK Biopharmaceuticals strike $2.5B AI drug discovery deal targeting neuroimmune therapies2
22.06.Insilico Rallies on Potential USD2.5 Billion Drug Discovery Pact With SK Biopharmaceuticals2
22.06.Insilico and SK Bio forge $2.5bn AI neuroimmunity alliance-
22.06.Insilico, SK Biopharmaceuticals Sign $2.5 Bln AI Drug Discovery Deal9
22.06.Insilico partners with SK BioPharmaceuticals in $2.5B AI drug pact1
22.06.INSILICO Enters R&D Collaboration with SK Biopharmaceuticals, Potential Deal Value Exceeds USD2.5 billion2
22.06.Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders577CAMBRIDGE, Mass., June 22, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery...
► Artikel lesen
22.06.INSILICO (03696): VOLUNTARY ANNOUNCEMENT INSILICO MEDICINE AND SK BIOPHARMACEUTICALS ACHIEVED AI-POWERED R&D COLLABORATION WORTH UP TO USD2.5 BILLION ...4
17.06.Insilico Medicine: Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics236CAMBRIDGE, Mass. and HONG KONG, June 17, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage biotechnology company powered by generative...
► Artikel lesen
17.06.INSILICO (03696): VOLUNTARY ANNOUNCEMENT INSILICO MEDICINE COMPLETES FIRST-IN-HUMAN DOSING IN PHASE I CLINICAL STUDY OF AI-DRIVEN NLRP3 INHIBITOR ISM8969, ...2
15.06.INSILICO (03696): VOLUNTARY ANNOUNCEMENT INCLUSION IN CHINA SECURITIES INDEX SERIES6
Weiter >>
93 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1